Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688520.SS

STRONG SELLREMOVE

Sinocelltech Group Limited · Healthcare · China · $2.7B · Avg Vol: $13M/d

8
StockRank
Q
22
V
35
M
33
P/E (TTM)
—
ROE
-157.2%
D/E
3.8x
Dividend %
—
Director Trades · 180d
None in 180d →
Buybacks · 180d
None in 180d →
AI CONVICTION THESIS

Sinocelltech Group is a pre-profit biopharmaceutical company with high cash burn and significant clinical development risks. It lacks the validated, high-utilization manufacturing moat of a true CDMO, making it too speculative for our portfolio.

COMPANY DESCRIPTION

Sinocelltech Group Limited develops and commercializes biologics, including monoclonal antibodies, recombinant proteins, and vaccines. The company developed China's first domestically produced recombinant coagulation factor VIII for hemophilia A, capturing significant market share. It is a biopharmaceutical innovator with a diverse pipeline spanning oncology, immunology, and infectious diseases.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGR
Revenue151M279M371M231M15.1%
EPS-0.18-0.130.04-0.20—
Shares445M445M445M445M0.0%
Debt245M406M376M463M23.7%
Equity-35M-89M21M19M-9.0%
Op CF-63M-57M18M-41M—
Inv CF-81M-74M-55M-43M—
Fin CF236M31M40M151M—
Loading...
PRICE (1M)-19.3%
4.905.315.726.136.53May 8May 29Jun 18
SMA 50SMA 200
Close
$5.04
RSI (14)
31.5
52W High
$13.16
From 52W High
0.4%

SCORE BREAKDOWN

Quality
22
ROIC
-44.1%16.2
ROE
-157.2%4.6
GP/Assets
32.1%68.2
Op. Margin
-36.6%22.9
FCF/Assets
-6.1%33.9
Piotroski
—7.2
Int. Cover
-5.7x29.6
D/E Ratio
3.76x2.9
Current Ratio
0.98x9.5
Value
35
P/E (TTM)
—N/A
EV/EBITDA
-36.2x91.5
P/FCF
—N/A
P/B
18.8x5.3
P/S
11.7x23.5
Div Yield
—N/A
Momentum
33
52W High %
38%11.1
RS 6M
-36%34.7
SMA 50/200
0.86x22.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+180%85.7
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$2.7B
P/E (Forward)
22.7x
Gross Margin
89.6%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688520.SS are excluded.

TickerCompanyMkt CapStockRankSignal
688520.SSSinocelltech Group Limited(you)$2.7B8STRONG SELL
9606.HKDuality Biotherapeutics, Inc.$2.6B11STRONG SELL
7666.HKMETIS TECHBIO-P$2.2B7STRONG SELL
688166.SSBrightGene Bio-Medical Technology Co., Ltd.$3.3B11STRONG SELL
688062.SSMabwell (Shanghai) Bioscience Co., Ltd.$2.0B3STRONG SELL
6855.HKAscentage Pharma Group International$1.9B4STRONG SELL
2617.HKTransThera Sciences (Nanjing), Inc.$1.8B4STRONG SELL
688382.SSInventisBio Co., Limited$1.7B12STRONG SELL
AAPGAscentage Pharma Group Internat$1.9B2STRONG SELL
1877.HKShanghai Junshi Biosciences Co., Ltd.$2.8B21SELL

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.0%

Sinocelltech Group Limited (688520.SS) — Stock Score Summary

Sinocelltech Group Limited (688520.SS) has a MoatMap StockRank of 8/100 based on Quality (22/100), Value (35/100), and Momentum (33/100) factor scores. The current signal is STRONG SELL. Sinocelltech Group is a pre-profit biopharmaceutical company with high cash burn and significant clinical development risks. It lacks the validated, high-utilization manufacturing moat of a true CDMO, making it too speculative for our portfolio.

Sinocelltech Group Limited develops and commercializes biologics, including monoclonal antibodies, recombinant proteins, and vaccines. The company developed China's first domestically produced recombinant coagulation factor VIII for hemophilia A, capturing significant market share. It is a biopharmaceutical innovator with a diverse pipeline spanning oncology, immunology, and infectious diseases.

Key Financial Metrics

Price$5.04
Market Cap$2.7B
P/E (Forward)22.69
Price/Book18.76
Return on Equity-157.2%
Return on Invested Capital-44.1%
Debt/Equity376.30
Gross Margin89.6%
Operating Margin-36.6%
Revenue Growth-37.8%
Free Cash Flow$-5M

Sinocelltech Group Limited operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Sinocelltech Group Limited’s (688520.SS) StockRank?
MoatMap’s StockRank for Sinocelltech Group Limited (688520.SS) is 8/100, with a Strong Sell signal. It is a composite of Quality (22), Value (35), and Momentum (33) factor ranks across MoatMap’s 20,000+ stock universe.
Does Sinocelltech Group Limited have an economic moat?
Sinocelltech Group Limited (688520.SS) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Sinocelltech Group Limited a buy, hold, or sell?
MoatMap’s current signal for Sinocelltech Group Limited (688520.SS) is Strong Sell, based on a StockRank of 8/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Sinocelltech Group Limited in?
Sinocelltech Group Limited (688520.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).
Browse all ranked stocks688520.SS deep dive reportAI ChampionsHow we score stocksSense-check another stock